Critical

Cytokine release syndrome (immunotherapy)

Immunotherapy · Allergy / Immunology
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

A systemic inflammatory response after immune-effector therapies (CAR-T cells, bispecific antibodies, some monoclonal antibodies) with fever, hypotension and hypoxia, ranging from mild to life-threatening.

Red flags

  • Hypotension requiring vasopressors
  • Hypoxia requiring escalating oxygen
  • Neurological changes (ICANS)
  • Multi-organ dysfunction

Assessment

Differential diagnosis

  • Sepsis
  • Anaphylaxis / infusion reaction
  • Tumour lysis syndrome
  • Immune effector cell-associated neurotoxicity (ICANS)
  • Haemophagocytic lymphohistiocytosis

Investigations

  • Vital signs and CRS grading (fever, hypotension, hypoxia)
  • FBC, U&E, LFTs, CRP, ferritin
  • Cultures (concurrent infection common)
  • ABG/lactate
  • Assess for neurotoxicity (ICANS)

Management

  • Recognise and grade CRS; monitor closely
  • Provide supportive care: antipyretics, fluids for hypotension, oxygen
  • Exclude and treat concurrent infection empirically
  • For significant/persistent CRS give tocilizumab (IL-6 receptor blockade)
  • Add corticosteroids for tocilizumab-refractory or severe CRS or neurotoxicity
  • Escalate to ICU for vasopressor/ventilatory support; involve the treating haematology-oncology team

Drugs & doses

Tocilizumab (IL-6 receptor antagonist) for significant CRS
Corticosteroids for refractory/severe CRS and for neurotoxicity
IV fluids and vasopressors for hypotension
Oxygen; empirical antibiotics if infection cannot be excluded

Disposition

ICU/HDU with the treating cellular therapy/haematology team.

Complications & pitfalls

  • Distributive shock
  • Respiratory failure
  • Neurotoxicity (ICANS)
  • Multi-organ failure / HLH-like syndrome

Exam pearls

  • Tocilizumab is the specific therapy for CRS; steroids are added for refractory disease and are first-line for the associated neurotoxicity
  • CRS and sepsis look identical - treat for infection concurrently
  • These patients need a specialist centre familiar with immune-effector toxicities

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.